Fortrea Holdings Inc.
FTRE$17.69
$-1.36 (-7.14%)-7.14%
ClosedLoading chart...
IndexN/A
Market Cap1.68B
Enterprise Value2.51B
Income$-0.56B
Sales$0.65B
EmployeesN/A
P/E31.59
P/S0.58
P/B2.79
P/C17.82
EV/EBITDA-3.09
EV/SalesN/A
EPS (ttm)0.56
EarningsN/A
Gross Margin15.63%
Oper. Margin-1.12%
Profit Margin-36.21%
Volume1.23M
Shs Outstand0.10B
Change-7.14%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $2.70B | $2.84B | $2.84B | $3.06B | $2.58B |
| Cost of Revenue | $2.16B | $2.25B | $2.11B | $2.45B | $2.09B |
| Gross Profit | $534.20M | $590.60M | $724.40M | $604.40M | $489.10M |
| Gross Margin | 19.81% | 20.78% | 25.53% | 19.77% | 18.96% |
| Operating Expenses | $696.10M | $558.60M | $537.30M | $490.10M | $803.30M |
| Operating Income | $-161.90M | $32.00M | $187.10M | $114.30M | $-314.20M |
| Operating Margin | -6.00% | 1.13% | 6.59% | 3.74% | -12.18% |
| Net Income | $-328.50M | $-25.20M | $186.20M | $98.00M | $-359.20M |
| Net Margin | -12.18% | -0.89% | 6.56% | 3.21% | -13.92% |
| EPS (Basic) | $-3.67 | $-0.04 | $2.11 | $1.11 | $-4.06 |
| EBITDA | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $3.58B | $4.33B | $4.29B | $4.37B | $0.00 |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.22B | $2.62B | $945.30M | $1.11B | $0.00 |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $1.36B | $1.71B | $3.34B | $3.26B | $0.00 |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.36B | $1.71B | $3.34B | $3.26B | $0.00 |
| Total Liabilities & Stockholders Equity | $3.58B | $4.33B | $4.29B | $4.37B | $0.00 |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Net Income | $-328.50M | $-25.20M | $186.20M | $98.00M | $-359.20M |
| Depreciation | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $262.80M | $168.40M | $82.70M | $169.80M | $200.90M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Fortrea Holdings Inc. (FTRE) Upgraded to Strong Buy: Here's What You Should Knowzacks.com FTRE vs. ARGX: Which Stock Is the Better Value Option?zacks.com Best Momentum Stock to Buy for July 31stzacks.com Fortrea Holdings Inc. (FTRE) Is Attractively Priced Despite Fast-paced Momentumzacks.com Fortrea Holdings Inc. (FTRE) Q2 2026 Earnings Call Transcriptseekingalpha.com Fortrea Q2 Earnings Call Highlightsmarketbeat.com Fortrea Holdings Inc. (FTRE) Surpasses Q2 Earnings and Revenue Estimateszacks.com Fortrea Reports Second Quarter 2026 Resultsglobenewswire.com
Show 12 more stories
Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firmbusinesswire.com Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Callglobenewswire.com Stocks Look Shaky, But This Sector is Booming (Biotech)zacks.com FTRE or ARGX: Which Is the Better Value Stock Right Now?zacks.com New Strong Buy Stocks for July 7thzacks.com Fortrea Names Jason Knoblauch as Chief Financial Officerglobenewswire.com Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com Fortrea to Attend Jefferies Global Healthcare Conferenceglobenewswire.com Fortrea to Attend Jefferies Global Healthcare Conferenceglobenewswire.com Fortrea Holdings Inc. (FTRE) Q1 2026 Earnings Call Transcriptseekingalpha.com Fortrea Holdings Inc. (FTRE) Beats Q1 Earnings Estimateszacks.com Fortrea Reports First Quarter 2026 Resultsglobenewswire.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Discover more
You may be interested in